Thymosin Beta-4
Also known as: Thymosin β4, Tβ4, TB4, RGN-259 (ophthalmic formulation)
A naturally occurring human peptide central to actin regulation, cell migration, and wound repair. Unlike the research-chemical fragment TB-500, the full protein has reached investigational human trials — most notably as an eye-drop (RGN-259) — but it is not FDA-approved for any use.
Not FDA-approved for any indication. The ophthalmic formulation RGN-259 has completed Phase III trials for neurotrophic keratopathy and holds orphan-drug designation, but has no marketing approval. Injectable Thymosin beta-4 sold outside of clinical trials is an unapproved research chemical, not a regulated medicine.
What it is
Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid peptide found in nearly all human cells. Its best-defined job is binding and sequestering G-actin, which lets it regulate the cell’s cytoskeleton — and, through that, cell migration, angiogenesis, and the mobilization of stem and progenitor cells during repair. It is the parent molecule behind the popular research chemical TB-500, but it is a different, better-studied entity: where TB-500 is a synthetic fragment sold with no human data, Tβ4 itself has reached formal clinical trials.
What it’s approved or studied for
Thymosin beta-4 is not FDA-approved for any indication. Its most advanced clinical program is RGN-259, a 0.1% Tβ4 eye-drop developed for corneal wound-healing disorders such as neurotrophic keratopathy and dry eye disease. RGN-259 has completed Phase III testing and holds orphan-drug designation, but it has not received marketing approval. Earlier trials also explored dermal wound healing.
What human evidence exists
The strongest human evidence is ophthalmic and Grade C (preliminary). A randomized, placebo-controlled, double-masked Phase III trial of RGN-259 in neurotrophic keratopathy reported complete corneal healing in 6 of 10 treated patients versus 1 of 8 on placebo, alongside symptom improvement and no significant adverse effects. That is a genuine, controlled human signal — but from a small trial, in a narrow indication, with a topical formulation. The broader “regeneration” claims (cardiac, tendon, muscle) rest on Grade D preclinical animal data. Long-term safety of systemic dosing is Grade U.
The major unknowns
Whether the promising ophthalmic results generalize to other tissues, the pharmacokinetics and safety of injected/systemic Tβ4 in humans, and effective dosing outside of a controlled trial are all open. As with any pro-angiogenic agent, effects on tumor biology are a theoretical concern that human data have not resolved. Research-chemical Tβ4 sold for injection is not the same, from an evidence or quality standpoint, as the formulations used in clinical trials.
Most important safety considerations
Within the ophthalmic trials, Tβ4 was generally well tolerated. Outside of them, systemic use is unproven and unregulated: there is no established human safety profile for injection, product quality is uncontrolled, and it is prohibited in sport at all times under WADA’s S2 category. This page summarizes the research record; it is not medical advice or an endorsement of use.
Evidence by outcome
Each outcome is graded on its own evidence — a compound can be strong for one use and unproven for another. See how we grade.
Preliminary human evidence from small controlled trials. — A randomized, placebo-controlled, double-masked Phase III trial of 0.1% RGN-259 eye drops reported complete corneal healing in 6 of 10 treated patients vs 1 of 8 on placebo, with symptom improvement and no significant adverse effects. Promising but small; not yet an established, approved therapy.
Early human and strong animal data; not established. — Earlier clinical work and extensive animal models support a wound-healing effect, but the evidence base is limited and no product is approved for this use.
Preclinical signal; human benefit not demonstrated. — Animal models show reduced scarring and improved cardiac function after ischemic injury; human trials have not confirmed a clinical benefit.
Preclinical only — the basis for TB-500 marketing. — Rodent injury models underlie the popular "healing peptide" claims, but there is no controlled human trial for these indications.
Unknown — long-term human safety of systemic dosing is not established.
Safety
Common adverse effects
- In the ophthalmic trials
- generally well tolerated with no significant adverse effects reported; systemic-dosing side-effect profile in humans is not established
Serious risks
- Not established for systemic use; theoretical concern that pro-angiogenic activity could influence tumor growth; unregulated product quality for research-chemical supply
Contraindications
- No established human contraindications; not an approved therapy for self-administration
References
- Sosne G, Kleinman HK, et al. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing in Neurotrophic Keratopathy: a Phase III Randomized, Placebo-Controlled Trial. Int. J. Mol. Sci. (2022)
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy (2012)